Core Insights - Evercore reported a revenue of $838.86 million for the quarter ended June 2025, reflecting a year-over-year increase of 20.7% and a surprise of +17.65% over the Zacks Consensus Estimate of $713.03 million [1] - The earnings per share (EPS) for the quarter was $2.42, compared to $1.81 in the same quarter last year, resulting in an EPS surprise of +35.96% against the consensus estimate of $1.78 [1] Financial Performance Metrics - Adjusted Net Revenues from Investment Banking & Equities totaled $788.23 million, exceeding the average estimate of $682.78 million by two analysts, representing a year-over-year increase of +16.9% [4] - Adjusted Net Revenues from Other Revenue, net, were reported at $29.13 million, significantly higher than the average estimate of $17.11 million, marking a year-over-year change of +65.6% [4] - Adjusted Net Revenues from Investment Management, specifically Asset Management and Administration Fees, amounted to $21.49 million, slightly below the average estimate of $22.25 million, with a year-over-year change of +2.8% [4] Stock Performance - Over the past month, Evercore's shares have returned +9.4%, outperforming the Zacks S&P 500 composite's +3.4% change [3] - The stock currently holds a Zacks Rank 1 (Strong Buy), indicating potential for outperformance in the near term [3]

Core Insights - Bausch + Lomb reported $1.28 billion in revenue for Q2 2025, a 5.1% year-over-year increase, with an EPS of $0.07 compared to $0.13 a year ago, indicating a decline in earnings per share [1] - The revenue exceeded the Zacks Consensus Estimate of $1.25 billion by 2.37%, while the EPS surpassed the consensus estimate of $0.06 by 16.67% [1] Revenue Breakdown - Vision Care revenues reached $753 million, exceeding the average estimate of $742.89 million, reflecting an 8% year-over-year increase [4] - Surgical revenues were reported at $216 million, surpassing the average estimate of $180.14 million, with a year-over-year change of 3.4% [4] - Pharmaceutical revenues totaled $309 million, slightly below the estimated $329.52 million, showing a minor decline of 0.3% year-over-year [4] - Total product sales amounted to $1.27 billion, exceeding the average estimate of $1.25 billion, representing a 4.9% year-over-year increase [4] - Other revenues were reported at $6 million, above the estimated $4 million, marking a significant 100% year-over-year increase [4] Stock Performance - Bausch + Lomb shares have returned +8.9% over the past month, outperforming the Zacks S&P 500 composite's +3.4% change [3] - The stock currently holds a Zacks Rank 5 (Strong Sell), suggesting potential underperformance relative to the broader market in the near term [3]

Core Insights - V.F. Corporation (VFC) reported a revenue of $1.76 billion for the quarter ended June 2025, reflecting a year-over-year decline of 7.7% and an EPS of -$0.24, an improvement from -$0.33 a year ago [1] - The revenue exceeded the Zacks Consensus Estimate of $1.69 billion by 3.96%, while the EPS surprised positively by 31.43% compared to the consensus estimate of -$0.35 [1] Financial Performance - The company's shares returned +1.3% over the past month, underperforming the Zacks S&P 500 composite's +3.4% change [3] - VFC holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3] Geographic Revenue Breakdown - Americas: $937.6 million, below the average estimate of $951.6 million, with a year-over-year decline of 10.3% [4] - Europe: $551.3 million, exceeding the estimate of $495.87 million, with a slight year-over-year decline of 0.3% [4] - Asia-Pacific: $271.8 million, below the estimate of $278.36 million, with a year-over-year decline of 12.2% [4] Revenue by Segment - Outdoor: $812.47 million, slightly below the estimate of $832.32 million, with a year-over-year increase of 2.8% [4] - Active: $699.69 million, above the estimate of $691.15 million, but reflecting a significant year-over-year decline of 25.7% [4] Revenue by Brand - The North Face: $557.4 million, exceeding the estimate of $523.34 million, with a year-over-year increase of 6.3% [4] - Vans: $498 million, above the estimate of $472.72 million, but showing a year-over-year decline of 14.4% [4] - Timberland: $255.1 million, surpassing the estimate of $230.92 million, with a year-over-year increase of 11.2% [4] Revenue by Channel - Direct-To-Consumer: $720.7 million, below the estimate of $748.72 million, with a year-over-year decline of 18% [4] Segment Profit (Loss) - Active: $56.84 million, below the estimate of $66.22 million [4] - Outdoor: $-42.27 million, better than the estimate of $-78.77 million [4]

Core Insights - Arch Capital Group (ACGL) reported a revenue of $4.76 billion for the quarter ended June 2025, reflecting a year-over-year increase of 20.9% [1] - The earnings per share (EPS) for the quarter was $2.58, slightly up from $2.57 in the same quarter last year, with an EPS surprise of +11.69% compared to the consensus estimate of $2.31 [1] Financial Performance Metrics - The underwriting expense ratio was reported at 28.1%, slightly above the average estimate of 27.8% [4] - The combined ratio stood at 81.2%, better than the estimated 82.2% [4] - The loss ratio was reported at 53.1%, also better than the estimated 54.3% [4] - Net investment income was $405 million, exceeding the average estimate of $401.06 million, representing a year-over-year increase of +11.3% [4] - Net premiums earned totaled $4.34 billion, surpassing the average estimate of $4.17 billion, with a year-over-year change of +21.7% [4] - Net premiums earned in the insurance segment were $1.97 billion, compared to the average estimate of $1.89 billion, reflecting a +33.2% year-over-year change [4] - Net premiums earned in the reinsurance segment were $2.06 billion, exceeding the average estimate of $2 billion, with a +15.7% year-over-year change [4] - Net premiums earned in the mortgage segment were $281 million, below the average estimate of $295.12 million, indicating an -8.5% year-over-year change [4] - Other underwriting income was reported at $62 million, significantly higher than the average estimate of $20.66 million, representing a +1966.7% year-over-year change [4] - Equity in net income of investment funds was $162 million, compared to the average estimate of $132.36 million, showing a -3% year-over-year change [4] - Other income was reported at $18 million, exceeding the average estimate of $2.33 million, reflecting a +125% year-over-year change [4] Stock Performance - Arch Capital's shares have returned -5% over the past month, while the Zacks S&P 500 composite has increased by +3.6% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]

Core Insights - Starbucks reported revenue of $9.46 billion for the quarter ended June 2025, reflecting a year-over-year increase of 3.8% [1] - The company's EPS was $0.50, down from $0.93 in the same quarter last year, indicating a significant decline [1] - The revenue exceeded the Zacks Consensus Estimate of $9.3 billion by 1.68%, while the EPS fell short of the consensus estimate of $0.65 by 23.08% [1] Financial Performance Metrics - Total stores reached 41,097, slightly below the average estimate of 41,148 from eight analysts [4] - Comparable store sales in North America decreased by 2%, compared to an estimated decline of 1.9% [4] - Comparable store sales internationally showed no growth, falling short of the estimated growth of 2.3% [4] - Net revenues from North America were $6.93 billion, surpassing the average estimate of $6.88 billion, with a year-over-year increase of 1.6% [4] - Net revenues from company-operated stores internationally were $1.53 billion, slightly above the estimate of $1.52 billion, marking a 10.6% year-over-year increase [4] - Net revenues from licensed stores internationally were $465.1 million, close to the estimate of $467.92 million, with a year-over-year increase of 3.9% [4] - Net revenues from licensed stores in North America were $640.5 million, below the estimate of $659.42 million, reflecting a year-over-year decline of 6% [4] - Net revenues from company-operated stores totaled $7.81 billion, exceeding the estimate of $7.71 billion, with a year-over-year increase of 3.9% [4] - Net revenues from licensed stores amounted to $1.11 billion, slightly below the estimate of $1.12 billion, indicating a year-over-year decline of 2.1% [4] - Net revenues from other sources were $537.9 million, surpassing the estimate of $471.17 million, with a year-over-year increase of 14.7% [4] - Net revenues from channel development reached $483.8 million, exceeding the estimate of $441.13 million, with a year-over-year increase of 10.4% [4] Stock Performance - Starbucks shares returned +2.2% over the past month, underperforming the Zacks S&P 500 composite's +3.6% change [3] - The stock currently holds a Zacks Rank 4 (Sell), suggesting potential underperformance relative to the broader market in the near term [3]

Core Insights - Camping World (CWH) reported revenue of $1.98 billion for the quarter ended June 2025, reflecting a year-over-year increase of 9.4% [1] - The company's EPS was $0.57, up from $0.38 in the same quarter last year, although it fell short of the consensus estimate of $0.58 by 1.72% [1] - The revenue exceeded the Zacks Consensus Estimate of $1.88 billion by 5.04% [1] Financial Performance Metrics - New vehicle unit sales reached 26,696, surpassing the average estimate of 22,432 [4] - Used vehicle unit sales were 18,906, exceeding the average estimate of 18,170 [4] - Average gross profit per unit for used vehicles was $6,190, higher than the average estimate of $5,851.75 [4] - Average selling price for used vehicles was $30,269, compared to the average estimate of $30,005.27 [4] - Average gross profit per unit for new vehicles was $4,729, below the average estimate of $5,320.90 [4] Revenue Breakdown - Revenue from RV and Outdoor Retail products, services, and other was $222.89 million, below the average estimate of $241.07 million, representing a year-over-year decline of 5.5% [4] - Revenue from RV and Outdoor Retail finance and insurance was $201.2 million, exceeding the average estimate of $185.26 million, with a year-over-year increase of 12.4% [4] - Revenue from RV and Outdoor Retail used vehicles was $572.27 million, surpassing the average estimate of $539.28 million, reflecting a year-over-year increase of 19% [4] - Revenue from RV and Outdoor Retail new vehicles was $915.11 million, exceeding the average estimate of $854.12 million, with a year-over-year increase of 8% [4] - Total revenue from RV and Outdoor Retail was $1.92 billion, above the average estimate of $1.82 billion, representing a year-over-year increase of 9.6% [4] - Revenue from the Good Sam Club was $10.27 million, below the average estimate of $11.32 million, indicating a year-over-year decline of 7.6% [4] - Revenue from Good Sam Services and Plans was $54.21 million, slightly below the average estimate of $55.21 million, reflecting a year-over-year increase of 3.2% [4] Stock Performance - Shares of Camping World have returned +4.1% over the past month, outperforming the Zacks S&P 500 composite's +3.6% change [3] - The stock currently holds a Zacks Rank 4 (Sell), suggesting potential underperformance relative to the broader market in the near term [3]

Qorvo (QRVO) reported $818.78 million in revenue for the quarter ended June 2025, representing a year-over- year decline of 7.7%. EPS of $0.92 for the same period compares to $0.87 a year ago. View all Key Company Metrics for Qorvo here>>> The reported revenue compares to the Zacks Consensus Estimate of $774.7 million, representing a surprise of +5.69%. The company delivered an EPS surprise of +48.39%, with the consensus EPS estimate being $0.62. Shares of Qorvo have returned -0.7% over the past month versu ...

Core Insights - Penumbra reported revenue of $339.46 million for the quarter ended June 2025, reflecting a year-over-year increase of 13.4% and surpassing the Zacks Consensus Estimate by 3.54% [1] - Earnings per share (EPS) for the quarter was $0.86, up from $0.64 in the same quarter last year, exceeding the consensus estimate of $0.81 by 6.17% [1] Financial Performance - The company's revenue from the United States was $260.82 million, a 19.5% increase compared to the previous year, and also above the average estimate of $257.86 million [4] - International revenue totaled $78.64 million, slightly above the average estimate of $70.83 million, but represented a year-over-year decline of 3.2% [4] - Revenue from Thrombectomy in the United States was reported at $188.53 million, closely aligning with the average estimate of $188.29 million [4] - The Embolization and Access segment in the United States generated $72.29 million, exceeding the average estimate of $69.57 million [4] - Total revenue from Embolization and Access was $109.2 million, significantly above the average estimate of $98.24 million, marking a year-over-year increase of 13.9% [4] - Thrombectomy revenue was reported at $230.26 million, slightly below the average estimate of $230.45 million, but still reflecting a year-over-year increase of 13.2% [4] Stock Performance - Over the past month, Penumbra's shares have decreased by 10.3%, contrasting with a 3.6% increase in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]

Core Insights - AstraZeneca reported revenue of $14.46 billion for the quarter ended June 2025, reflecting an 11.7% increase year-over-year and a surprise of +3.04% over the Zacks Consensus Estimate of $14.03 billion [1] - The company's EPS for the quarter was $1.09, unchanged from the consensus estimate, compared to $0.99 in the same quarter last year [1] Financial Performance Metrics - AstraZeneca's stock has returned +2.8% over the past month, while the Zacks S&P 500 composite increased by +3.6% [3] - The company holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3] Segment Performance - BioPharmaceuticals - CVRM - Farxiga: $106 million, +2.9% year-over-year, slightly below the average estimate of $106.86 million [4] - BioPharmaceuticals - V&I - Europe: $24 million, +242.9% year-over-year, significantly above the average estimate of $15.81 million [4] - BioPharmaceuticals - CVRM - Lokelma: $37 million, +32.1% year-over-year, above the average estimate of $34.81 million [4] - BioPharmaceuticals - CVRM - Crestor: $32 million, -11.1% year-over-year, below the average estimate of $35.95 million [4] - Oncology - Tagrisso: $209 million, +9.4% year-over-year, slightly below the average estimate of $215.72 million [4] - Oncology - Imfinzi: $174 million, -4.9% year-over-year, below the average estimate of $191.28 million [4] - Oncology - Lynparza: $69 million, +4.6% year-over-year, below the average estimate of $74.14 million [4] - Oncology - Calquence: $42 million, +27.3% year-over-year, above the average estimate of $36.78 million [4] - Overall Oncology: $591 million, +5.4% year-over-year, below the average estimate of $607.27 million [4] - BioPharmaceuticals - R&I - Symbicort: $91 million, +9.6% year-over-year, above the average estimate of $86.31 million [4] - BioPharmaceuticals - R&I - Fasenra: $44 million, +18.9% year-over-year, above the average estimate of $42.25 million [4] - BioPharmaceuticals - R&I - Breztri: $25 million, +31.6% year-over-year, slightly above the average estimate of $24.8 million [4]

Core Insights - UnitedHealth Group reported $111.62 billion in revenue for Q2 2025, a year-over-year increase of 12.9% [1] - The EPS for the same period was $4.08, down from $6.80 a year ago, representing a surprise of -15.7% compared to the consensus estimate of $4.84 [1] Financial Performance - The reported revenue exceeded the Zacks Consensus Estimate of $111.55 billion by 0.06% [1] - The company’s stock has returned -9.6% over the past month, underperforming the Zacks S&P 500 composite's +3.6% change [3] Key Operating Metrics - Medical Care Ratio was reported at 89.4%, slightly above the average estimate of 88.6% [4] - UnitedHealthcare served 8.44 million risk-based customers, slightly below the average estimate of 8.48 million [4] - Total community and senior customers served were 20.15 million, compared to the average estimate of 20.28 million [4] Revenue Breakdown - Investment and other income was $1.11 billion, exceeding the average estimate of $1.03 billion, with a year-over-year change of +11.1% [4] - Products revenue was $13.56 billion, matching the average estimate, with a year-over-year change of +11.1% [4] - Services revenue was $9.04 billion, below the average estimate of $9.37 billion, with a year-over-year change of +3.3% [4] - Premiums revenue reached $87.91 billion, surpassing the average estimate of $87.23 billion, reflecting a +14.3% year-over-year change [4] - Optum Insight revenue was $4.83 billion, below the average estimate of $5.17 billion, with a +6.3% year-over-year change [4] - Optum Rx revenue was $38.46 billion, exceeding the average estimate of $36.43 billion, with an +18.7% year-over-year change [4] - Optum Health revenue was $25.21 billion, below the average estimate of $26.88 billion, reflecting a -6.8% year-over-year change [4] - Total revenue for UnitedHealthcare was $86.1 billion, surpassing the average estimate of $84.75 billion, with a +16.6% year-over-year change [4]